Neutralizing shapeshifting pericytes enhances glioblastoma therapeutic efficacy

Maraviroc, an FDA-approved therapy, provides a potentially viable treatment option for those diagnosed with glioblastoma harboring a high amount of pericyte support cells.

Automated summary

Maraviroc, an FDA-approved therapy, may be a potentially viable treatment option for patients diagnosed with glioblastoma harboring a high amount of pericyte support cells.